Tuesday, March 31, 2020

Biocon#39;s insulin manufacturing facility in Malaysia gets EIR with VAI classification From USFDA

Biocon#39;s insulin manufacturing facility in Malaysia gets EIR with VAI classification From USFDA In a regulatory filing the company said, Biocon Sdn Bhd, a subsidiary of Biocon Ltd has received the EIR from the USFDA for the Pre-Approval Inspection (PAI) of its insulin manufacturing facility in Malaysia, for Insulin Glargine.

from Moneycontrol Business News https://ift.tt/3azKKTG
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Vedanta, Hindustan Zinc shares fall after metals giant confirms ED visits to offices

Vedanta and Hindustan Zinc shares dipped after the Enforcement Directorate visited some of their offices as part of a FEMA probe. The compan...